BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antisense Therapeutics Limited (ANP.AX) Receives Approval To Restart Phase IIa Trial Of ATL1102 For Patients With Multiple Sclerosis


1/18/2006 10:41:42 AM

MELBOURNE, Australia, Jan. 18 /PRNewswire-FirstCall/ -- Antisense Therapeutics Limited has received approval from the Ethics Committee of the University of Essen in Germany to restart the Phase IIa trial of its antisense compound, ATL1102, for patients with relapsing-remitting Multiple Sclerosis. The University of Essen is the primary trial site for the Phase IIa clinical trial. Patient enrollment and dosing are expected to commence at this center in the February/March timeframe.

This multi-center, randomized, double-blinded, placebo-controlled Phase IIa clinical trial is designed to assess the activity and safety of ATL1102 in 80 MS patients. The drug will be delivered by subcutaneous injection on a twice-a-week dosing schedule at a dose of 400 mg per week. The goal of the Phase IIa trial is to obtain preliminary evidence of the drug's effectiveness, which will be evaluated using MRI indices. MRI's will be conducted at monthly intervals over the eight-week dosing period and at monthly intervals during the eight-week period following completion of dosing.

The treatment and patient monitoring stages of the trial are expected to conclude by the end of 2006, assuming patient recruitment proceeds as scheduled. The University of Essen will be the primary site for the trial, with eight other trial centers in Germany to be initiated in the coming months.

"We are pleased to receive approval from the University of Essen to restart the Phase IIa trial and advance the development of ATL1102," said Mark Diamond, Chief Executive Officer. "This follows the unanimous recommendation we received to continue the development of the compound as a treatment for patients with MS from the independent Medical Advisory Board that we convened last March to evaluate the most appropriate development path for the drug. ATL1102 represents a novel therapeutic approach to the treatment of MS, which as stated by the Medical Advisory Board, appears to have significant potential as a therapeutic agent for patients with the relapsing-remitting form of the disease."

Multiple sclerosis is a life long chronic disease of the central nervous system, which is believed to affect as many as 2.5 million people worldwide. While existing drug sales for this disease were greater than US$4 billion in 2004, there remains a high demand for more effective and better-tolerated treatments.

About ATL1102 for MS

ATL1102 is a second-generation antisense inhibitor of CD49d, an immune system protein known as VLA-4 (Very Late Antigen-4), and is currently in development as a treatment for MS. The Antisense compound is designed to block the synthesis of VLA-4, which is known to play a part in both the onset and progression of Multiple Sclerosis. In inflammation, white blood cells (leukocytes) move out of the bloodstream into the inflamed tissue, for example, the CNS in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby halting progression of the disease. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of animal models of inflammatory disease including MS. The mechanism of action of ATL1102 in blocking VLA-4 is different to other drugs in development that target this same protein, including the monoclonal antibody Tysabri(R).

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. ANP's mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. The company's product pipeline includes ATL1102 for Multiple Sclerosis, and ATL1101 for Psoriasis, both of which have advanced to the stage of human clinical trials and ATL1103, a potential treatment for growth (acromegaly) and sight disorders (diabetic retinopathy and wet-are related macular degeneration), which is in pre-clinical development. For additional information about Antisense Therapeutics and the compounds it is developing, visit the company web site http://www.antisense.com.au.

ANP's major shareholders include Circadian Technologies Limited and Isis Pharmaceuticals Inc.

CONTACT INFORMATION: Company US Investors Mark Diamond Kathy Price Chief Executive Officer The Global Consulting Group Tel: +61-3-9827-8999 Tel: +646 284-9430 Email: mark.diamond@antisense.com.au Email: kprice@hfgcg.com

Antisense Therapeutics Limited

CONTACT: Mark Diamond, Chief Executive Officer of Antisense TherapeuticsLimited, +61-3-9827-8999, mark.diamond@antisense.com.au; US Investors:Kathy Price of The Global Consulting Group, +1-646-284-9430,kprice@hfgcg.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES